Sanofi SNY
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 84th percentile, 5-year average 17.8x
#1847 of 2972 stocks by PE (1 = cheapest)
Near the bottom of its 5-year range · 19th percentile, 5-year average 1.5x
#2145 of 5311 stocks by PB (1 = cheapest)
Near the bottom of its 5-year range · 5th percentile, 5-year average 2.4x
#2417 of 5150 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 1.37 | – | 1.53 | 19% (cheaper than usual) | #2145 of 5311 (1 = cheapest) |
| PE | 24.26 | 10.81 | 17.78 | 84% (pricier than usual) | #1847 of 2972 (1 = cheapest) |
| PS | 1.87 | 1.90 | 2.45 | 5% (cheaper than usual) | #2417 of 5150 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on SNY.
Sign in to join the discussion.